Nurix Therapeutics Inc Surges on Positive Clinical Data
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 15 2024
0mins
Source: Business Insider
Nurix Therapeutics Inc saw a significant price increase of 18.19%, crossing above its 5-day SMA amid a challenging market environment.
The surge follows the announcement of promising clinical data for Bexobrutideg, which achieved an 83% objective response rate in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) during its Phase 1a study. This data highlights the drug's potential effectiveness and safety profile, encouraging investor confidence.
As Nurix prepares for further clinical trials and discussions regarding Bexobrutideg, the positive results may position the company favorably in the competitive biotech landscape, potentially attracting more investment and interest in its future developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NRIX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NRIX
Wall Street analysts forecast NRIX stock price to rise
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 17.120
Low
22.00
Averages
31.08
High
41.00
Current: 17.120
Low
22.00
Averages
31.08
High
41.00
About NRIX
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, aimed at improving treatment options for patients with cancer and autoimmune diseases. The Company's wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The Company's portfolio of targeted protein degraders of the B‑cell signaling protein BTK comprises bexobrutideg (NX‑5948) and zelebrudomide (NX‑2127). The Company's degradation inhibitor program includes NX-1607, an orally bioavailable inhibitor of CBL-B, an E3 ligase that regulates the activation of multiple immune cell types including T cells and NK cells. NX-1607 is targeted for immuno-oncology indications.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Technological Revolution: Quantum computing is considered a technological revolution that could surpass AI, and while some believed it was years away, it is already advancing rapidly, indicating significant market potential.
- Industry Giants' Involvement: Major hyperscalers like Microsoft, Google, Amazon, Oracle, Meta, and Tesla are scrambling to integrate quantum computing into their infrastructure, highlighting the increasing importance of this technology and potentially sparking a new wave of competition.
- Investment Opportunities: Senior Stock Strategist Kevin Cook has identified seven carefully selected stocks poised to dominate the quantum computing landscape, providing investors with a unique opportunity to position themselves in this emerging field amid rapid technological advancements.
- Broad Market Outlook: Kevin Cook's recognition of NVIDIA's potential back in 2016 parallels his current focus on quantum computing, suggesting that this sector could become the next major investment hotspot, drawing significant investor interest.
See More
- Chipmaker Recovery: Following last Friday's selloff, chipmakers and AI-infrastructure stocks saw a modest recovery on Monday, with Intel (INTC) rising over 11% after Google placed an order for three million Tensor Processing Units, indicating sustained market demand for AI technology.
- Oil Price Volatility: WTI crude oil prices initially surged over 4% on Monday due to Iran's announcement of an end to military operations against Israel, but later retreated, highlighting market sensitivity to geopolitical risks and affecting investor demand for safe-haven assets.
- Interest Rate Expectations Shift: The market is pricing in only a 3% chance of a 25 bp rate hike at the upcoming FOMC meeting in June, reflecting investor concerns over slowing economic growth, which pushed the 10-year T-note yield to a two-week high of 4.580%, indicating tension over future monetary policy.
- Mixed International Market Performance: Overseas stock markets settled mixed on Monday, with the Euro Stoxx 50 falling to a two-week low while China's Shanghai Composite dropped 1.70%, demonstrating the impact of global economic uncertainty on market sentiment.
See More
- Market Rebound: The S&P 500 Index rose by 1.01%, the Dow Jones Industrial Average increased by 0.46%, and the Nasdaq 100 Index climbed by 2.39%, indicating a recovery from last Friday's selloff, particularly driven by strong performances in chipmakers and AI infrastructure stocks.
- Oil Price Volatility: WTI crude oil prices initially surged over 4% due to escalating tensions between Iran and Israel but retreated after Iran announced an end to its military operations, alleviating pressure on the stock market as expectations for a ceasefire emerged.
- Interest Rate Expectations: The market is pricing in only a 3% chance of a 25 basis point rate hike at the next FOMC meeting, reflecting a cautious outlook among investors, especially following robust nonfarm payroll data, which could influence bond market dynamics.
- Tech Stock Surge: Intel's stock surged by 11% after Google placed an order for three million Tensor Processing Units, driving a broader rally in chip stocks, highlighting the tech sector's critical role in the market recovery and potentially attracting more investor interest in related equities.
See More
- Apple Stock Surge: Apple's shares rose over 2% as its Worldwide Developers Conference commenced, with expectations to unveil its artificial intelligence strategy, including updates to Siri, which could further solidify its leadership in the tech industry.
- Wix Lowers Outlook: Wix.com saw its stock drop more than 5% after revising its full-year bookings growth forecast to the low teens percentage rate, down from mid-teens, which may negatively impact market confidence and investor sentiment.
- Crocs Rating Upgrade: Crocs' shares increased by 3% following Baird's upgrade to outperform, indicating a healthier narrative emerging in the North American market, which enhances investor confidence in its future growth prospects.
- Cerebras Stock Surge: Cerebras Systems experienced a 20% stock increase after several Wall Street firms initiated coverage with buy ratings, reflecting strong market confidence in its AI chip technology, potentially boosting its competitiveness in the rapidly evolving AI sector.
See More
- Market Rebound: The S&P 500 Index rose by 0.65%, the Dow Jones Industrial Average increased by 0.21%, and the Nasdaq 100 climbed by 1.59%, indicating market resilience following last week's sell-off, particularly driven by strong performances in chipmakers and AI infrastructure stocks.
- Oil Price Volatility: Crude oil prices fell from highs after Iran announced an end to its military operations against Israel, despite initially surging over 4% amid escalating conflict, highlighting the direct impact of geopolitical tensions on market sentiment.
- Interest Rate Expectations: The market is pricing in only a 1% chance of a 25 basis point rate hike at the upcoming FOMC meeting in June, reflecting cautious investor sentiment regarding future monetary policy, especially in light of stronger-than-expected US nonfarm payroll data.
- Stock Performances: In the stock market, Micron Technology surged over 9%, leading gains in the S&P 500 and Nasdaq 100, showcasing the recovery potential of the chip sector, while Nurix Therapeutics jumped over 17% after agreeing with Roche on a deal worth up to $2.3 billion.
See More
- NVIDIA Stock Performance: NVIDIA Corporation (NVDA) shares rose by $5.0025 to $210.10, with a trading volume of 9,170,323 shares, reflecting 10 upward revisions in earnings forecasts over the past four weeks, projecting an EPS of $1.99 for Q2 FY2026, indicating strong market confidence in its future performance.
- Nokia Market Dynamics: Nokia Corporation (NOK) saw its stock price increase by $0.51 to $14.89, with 9,085,724 shares traded, and its current mean recommendation remains in the 'buy range', reflecting investor optimism regarding its business outlook.
- ProShares ETF Performance: ProShares UltraPro QQQ (TQQQ) shares increased by $3.28 to $76.33, with a trading volume of 7,684,803 shares, representing a 113.75% rise from its 52-week low, showcasing strong demand for tech stocks among investors.
- Bitcoin Trust Fund Dynamics: iShares Bitcoin Trust ETF (IBIT) rose by $1.56 to $35.70, with 6,181,978 shares traded, following a previous 52-week high, indicating sustained market interest in cryptocurrencies.
See More











